Insulet/$PODD

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Insulet

Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device and that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, approximately 500,000 insulin-dependent diabetics are using it worldwide.

Ticker

$PODD
Primary listing

Industry

Health Care Equipment & Supplies

Employees

3,900

ISIN

US45784P1012

Insulet Metrics

BasicAdvanced
$22B
55.19
$5.55
1.27
-

What the Analysts think about Insulet

Analyst ratings (Buy, Hold, Sell) for Insulet stock.

Bulls say / Bears say

Insulet Corporation reported a 29% year-over-year revenue increase in Q1 2025, indicating strong demand for its Omnipod products. (Insulet Corporation)
The company achieved a gross margin of 72.1% in Q4 2024, reflecting improved operational efficiency and profitability. (BioSpace)
Insulet expanded its international presence by launching Omnipod 5 integrated with Abbott’s FreeStyle Libre 2 Plus CGM sensor in multiple European countries, potentially increasing its market share. (TradingView News)
In Q2 2024, Insulet recorded a $13.5 million charge for unutilized inventory, negatively impacting gross margin by approximately 280 basis points. (Reuters)
The company's adjusted profit per share in Q2 2024 was $0.55, slightly below analysts' expectations of $0.56, indicating potential challenges in meeting market forecasts. (Reuters)
Insulet's larger competitor, Dexcom, reduced its annual forecast in July 2024, raising concerns about changing trends in the diabetes market that could affect Insulet's growth. (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 9 Jun 2025.

Insulet Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Insulet Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $PODD

Sign up or log in to buy
Capital at risk
Market open

Upcoming events

No upcoming events
FAQs